NAD tells Good Life to drop compounded tirzepatide claims

BBB National Programs’ National Advertising Division (NAD) has recommended that Good Life Meds, LLC discontinue challenged health-benefit and personalization claims for its compounded tirzepatide products, sold as “Tirzepatide+.” The challenge was brought by Eli Lilly and Company. BBB National Programs announced the decision on November 4, 2026 at 11:00 a.m. Eastern.

Good Life runs a telehealth website that links customers with clinicians and pharmacies and sells prescription weight loss drugs. Lilly makes Mounjaro, approved for Type 2 diabetes, and Zepbound, approved for chronic weight management; the release calls them the only FDA-approved tirzepatide medicines. Lilly challenged Good Life’s claims about the efficacy, safety, FDA status and personalization of the compounded products.

Health-benefit claims

Good Life’s ads said the product helps with healthy weight loss, gives a natural energy boost and improves blood sugar control while keeping lean muscle. Read against the ads overall, NAD said, those statements told consumers that the finished compounded product, not just one of its ingredients, produces those effects.

To back the claims, Good Life offered published tirzepatide research, studies of the added ingredients, a Gallup survey and retrospective cohort studies. NAD said that record did not match the claims:

• Most of the tirzepatide research was on Lilly’s approved drugs.
• Nothing connected ingredient-level data to the compounded Tirzepatide+ itself.
• Neither the survey nor the cohort studies looked at Tirzepatide+.
• No evidence addressed whether tirzepatide combined with the additives is safe.
• FDA allowing compounding during shortages was not support for the claims.

NAD said Good Life had no reasonable basis for the express claims and recommended dropping them. It also recommended changes so the ads stop implying that Tirzepatide+ works safely for those benefits or delivers significant weight loss.

‘Personalized’ claims

Lilly also challenged claims that Tirzepatide+ is a “personalized medication… tailored to meet individual patient needs” and “compounded for your unique needs.” NAD said the ads overstated how individual the product is. A prescriber can pick from set formulations and doses and change the plan later, NAD said, but the drug is not made or formulated for one patient.

NAD recommended Good Life stop claiming Tirzepatide+ is “personalized,” “custom formulated,” “tailored to meet individual patient needs” and “compounded for your unique needs.”

Claims already dropped

While the case was open, Good Life said it had permanently stopped some other claims, covering clinical results, benefits, ingredients, safety and sourcing. For compliance purposes NAD handles those as if it had recommended dropping them.

In its advertiser statement, Good Life said that though it “disagrees with many aspects of NAD’s decision,” it “will comply with NAD’s recommendations.”

Context

What changes Good Life makes to its ads, and when, is not yet known. The decision comes days after FDA posted a warning letter, dated October 30, 2026, to RonanRx over claims about compounded semaglutide and tirzepatide (report). NAD is a self-regulatory body, not a regulator; for how FDA enforcement letters work, see FDA warning letters explained. FDA said in February that it would act against mass-marketed compounded GLP-1s (report).

The decision summary is in the BBB National Programs release.